Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation.
Igawa S, Kasajima M, Ishihara M, Kimura M, Hiyoshi Y, Niwa H, Kusuhara S, Harada S, Asakuma M, Otani S, Katono K, Sasaki J, Masuda N. Igawa S, et al. Among authors: hiyoshi y. Cancer Chemother Pharmacol. 2014 Nov;74(5):939-46. doi: 10.1007/s00280-014-2570-1. Epub 2014 Aug 31. Cancer Chemother Pharmacol. 2014. PMID: 25173459
Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer.
Igawa S, Otani S, Nakahara Y, Ryuge S, Hiyoshi Y, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sato Y, Sasaki J, Masuda N. Igawa S, et al. Among authors: hiyoshi y. Invest New Drugs. 2018 Feb;36(1):45-52. doi: 10.1007/s10637-017-0472-x. Epub 2017 May 2. Invest New Drugs. 2018. PMID: 28466376 Clinical Trial.
Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study.
Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, Mitsufuji H, Kubota M, Hiyoshi Y, Ishihara M, Kasajima M, Sasaki J, Naoki K. Fukui T, et al. Among authors: hiyoshi y. Clin Lung Cancer. 2019 May;20(3):208-214.e2. doi: 10.1016/j.cllc.2018.04.021. Epub 2018 May 5. Clin Lung Cancer. 2019. PMID: 29803573
Amrubicin monotherapy for elderly patients with relapsed extensive-disease small-cell lung cancer: A retrospective study.
Sone H, Igawa S, Kasajima M, Ishihara M, Hiyoshi Y, Hosotani S, Ohe S, Ito H, Kaizuka N, Manaka H, Fukui T, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K. Sone H, et al. Among authors: hiyoshi y. Thorac Cancer. 2018 Oct;9(10):1279-1284. doi: 10.1111/1759-7714.12833. Epub 2018 Aug 20. Thorac Cancer. 2018. PMID: 30126051 Free PMC article.
Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer.
Shirasawa M, Fukui T, Kusuhara S, Hiyoshi Y, Ishihara M, Kasajima M, Nakahara Y, Otani S, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K. Shirasawa M, et al. Among authors: hiyoshi y. Cancer Manag Res. 2018 Nov 21;10:6039-6047. doi: 10.2147/CMAR.S181789. eCollection 2018. Cancer Manag Res. 2018. PMID: 30538553 Free PMC article.
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.
Ono T, Igawa S, Ozawa T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Katagiri M, Naoki K. Ono T, et al. Among authors: hiyoshi y. Thorac Cancer. 2019 Apr;10(4):880-889. doi: 10.1111/1759-7714.13018. Epub 2019 Feb 28. Thorac Cancer. 2019. PMID: 30821083 Free PMC article.
278 results